Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö, Mustafayev FNA, Yaman Ş, Bayram E, Ertürk İ, Özcan E, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, Baytemür NK, Gülmez A, Aydın D, Şakalar T, Arak H, Tatlı AM, Ergün Y, Ak N, Ünal Ç, Özgün MA, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: erturk i. J Cancer Res Clin Oncol. 2023 Jul;149(8):4141-4148. doi: 10.1007/s00432-022-04252-2. Epub 2022 Sep 1. J Cancer Res Clin Oncol. 2023. PMID: 36048274
Vertebral sarcoidosis: an unusual presentation.
Ertürk A, Ertürk IO, Gülhan M, Canbakan S, Inönü H, Demirag F, Capan N. Ertürk A, et al. Among authors: erturk io. Sarcoidosis Vasc Diffuse Lung Dis. 2007 Sep;24(2):155-6. Sarcoidosis Vasc Diffuse Lung Dis. 2007. PMID: 18496989 No abstract available.
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Esin E, et al. Among authors: erturk i. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. Cancer Chemother Pharmacol. 2019. PMID: 30377778
The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer.
Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S, Bilgin B, Taban H, Kucukarda A, Erturk I, Hızal M, Yıldız B, Yıldırım N, Demirci U, Sendur MA, Utkan G, Kılıckap S, Cicin I, Karadurmus N, Ürün Y. Yasar HA, et al. Among authors: erturk i. J Oncol Pharm Pract. 2020 Jul;26(5):1110-1116. doi: 10.1177/1078155219883004. Epub 2019 Oct 25. J Oncol Pharm Pract. 2020. PMID: 31653193
Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study).
Hizal M, Sendur MA, Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S, Taban H, Kucukarda A, Erturk I, Bilgin B, Yıldırım N, Demirci U, Kılıckap S, Cicin I, Karadurmus N, Yalcin B, Ürün Y. Hizal M, et al. Among authors: erturk i. J Oncol Pharm Pract. 2020 Oct;26(7):1583-1589. doi: 10.1177/1078155219900908. Epub 2020 Feb 13. J Oncol Pharm Pract. 2020. PMID: 32054412
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study.
Yildiz B, Kucukarda A, Gokyer A, Gokcen Demiray A, Paydas S, Pinar Aral I, Gumusay O, Bilici A, Akdeniz N, Bahceci A, Demir H, Esin E, Üyeturk U, Nihat Okten I, Erturk I, Turk HM, Topaloglu US, Basoglu T, Serdar Turhal N, Yesil Cinkir H, Menekse S, Cakmak Y, Urun Y, Acar R, Kut E, Dal P, Sakalar T, Halit Aktepe O, Karadurmus N, Bilici A. Yildiz B, et al. Among authors: erturk i. J BUON. 2020 Mar-Apr;25(2):1130-1135. J BUON. 2020. PMID: 32521916 Free article.
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study.
Karadurmus N, Paydas S, Esin E, Surmeli ZG, Yildiz B, Erturk I, Nayir E, Dogan M, Sumbul AT, Barista I, Gurkan E, Ocal R, Ferhanoglu B, Ozgur G, Karakas Y, Lacin S, Ozaydin S, Petekkaya HI, Uskent N. Karadurmus N, et al. Among authors: erturk i. Arch Med Sci. 2019 Feb 18;17(4):920-927. doi: 10.5114/aoms.2019.83000. eCollection 2021. Arch Med Sci. 2019. PMID: 34336021 Free PMC article.
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz E, Ertürk İ, Tural D, Karadurmuş N, Karakaya S, Hızal M, Arıkan R, Arslan Ç, Taban H, Küçükarda A, Öztaş NŞ, Sever ÖN, Uçar G, Can O, Şendur MA, Demirci U, Kılıçkap S, Çiçin İ, Öksüzoğlu B, Özgüroğlu M, Ürün Y. Yekedüz E, et al. Among authors: erturk i. Future Oncol. 2021 Dec;17(35):4861-4869. doi: 10.2217/fon-2021-0717. Epub 2021 Nov 2. Future Oncol. 2021. PMID: 34726480
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
Yekedüz E, Tural D, Ertürk İ, Karakaya S, Erol C, Ercelep Ö, Arslan Ç, Sever ÖN, Kılıçkap S, Şentürk Öztaş N, Küçükarda A, Can O, Öksüzoğlu B, Şendur MA, Karadurmuş N, Ürün Y. Yekedüz E, et al. Among authors: erturk i. J Cancer Res Clin Oncol. 2022 Dec;148(12):3537-3546. doi: 10.1007/s00432-022-04055-5. Epub 2022 May 26. J Cancer Res Clin Oncol. 2022. PMID: 35616728
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
Gürbüz M, Kutlu Y, Akkuş E, Köksoy EB, Köse N, Öven BB, Uluç BO, Demiray AG, Erdem D, Demir B, Turhal NS, Üskent N, Akbaş S, Selçukbiricik F, İnal A, Bilici A, Ölmez ÖF, Çabuk D, Ünal Ç, Hızal M, Şendur MAN, Korkmaz M, Karadurmuş N, Ertürk İ, Göksu SS, Tatlı AM, Güven DC, Kılıçkap S, Paksoy N, Aydıner A, Çınkır HY, Özkul Ö, Öztürk A, Ballı S, Kemal Y, Erdoğan AP, Er Ö, Yumuk PF, Demirkazık A. Gürbüz M, et al. Among authors: erturk i. J Cancer Res Clin Oncol. 2022 Dec;148(12):3547-3555. doi: 10.1007/s00432-022-04087-x. Epub 2022 Jun 11. J Cancer Res Clin Oncol. 2022. PMID: 35689097
40 results